5-Aminosalicylate Therapy

  • M. Susan Moyer


Inflammatory Bowel Disease Ulcerative Colitis Crohn Disease Active Ulcerative Colitis Active Crohn Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sandborn WJ. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Rev Gastroenterol Disord 2006;6:97–105.PubMedGoogle Scholar
  2. 2.
    Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2006;23:841–55.PubMedCrossRefGoogle Scholar
  3. 3.
    Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:892–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Escher JC, Taminiau J, Nieuwenhuis E, et al.. Treatment of inflammatory bowel disease in childhood: Best available evidence. Inflamm Bowel Dis 2003;9:34–58.PubMedCrossRefGoogle Scholar
  5. 5.
    Lim W-C, Hanauer SB. Controversies with aminosalicylates in inflammatory bowel disease. Rev Gastroenterol Disord 2004;4:104–17.PubMedGoogle Scholar
  6. 6.
    Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete? World J Gastroenterol 2006;12:6115–23.Google Scholar
  7. 7.
    Levine DS, Riff DS, Pruitt R, et al. A randomized, double-blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002;97:1398–1407.PubMedGoogle Scholar
  8. 8.
    Fallingborg J, Christensen LA, Jacobsen BA, Rasmussen SN. Very low intraluminal colonic pH in patients with active ulcerative colitis. Dig Dis Sci 1993;38:1989–93.PubMedCrossRefGoogle Scholar
  9. 9.
    Qureshi AY, Cohen RD. Mesalamine delivery systems: do they really make much difference? Adv Drug Deliv Rev 2005;57:281–302.Google Scholar
  10. 10.
    Goldstein PD, Alpers DH, Keating JP. Sulfapyridine metabolites in children with inflammatory bowel disease receiving sulfasalazine. J Pediatr 1979;95:638–40.PubMedCrossRefGoogle Scholar
  11. 11.
    Klotz U. 5-aminosalicylic acid and chronic inflammatory bowel diseases in children. Klin Padiatr 1995;207:285–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Tolia V, Massoud N, Klotz U. Oral 5-aminosalicylic acid in children with colonic chronic inflammatory bowel disease: clinical and pharmacokinetic experience. J Pediatr Gastroenterol Nutr 1989;8:33–8.Google Scholar
  13. 13.
    Wiersma H, Escher JC, Dilger K, et al. Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease. Inflamm Bowel Dis 2004;10:626–31.PubMedCrossRefGoogle Scholar
  14. 14.
    Christensen LA, Fallingborg J, Jacobsen BA, et al. Bioavailability of 5-aminosalicylic acid from slow release 5-aminosalicylic acid drug and sulfasalazine in normal children. Dig Dis Sci 1993;38:1831–6.PubMedCrossRefGoogle Scholar
  15. 15.
    MacDermott RP. Progress in understanding the mechanism of action of 5-aminosalicylic acid. Am J Gastroenterol 2000;95:3343–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Nikolaus S, Folscn U, Schreiber S. Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease. Hepatogastroenterology 2000;47:71–82.PubMedGoogle Scholar
  17. 17.
    Bantel H, Berg C, Vieth M, et al. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000;95:3452–7.PubMedGoogle Scholar
  18. 18.
    Kornbluth A, Sachar DB. Practice parameters committee of the American college of gastroenterology. Ulcerative colitis practice guidelines in adults (update). Am J Gastroenterol 2004;99:1371–85.PubMedCrossRefGoogle Scholar
  19. 19.
    Margolin ML, Krumholz MP, Fiochios SE, Korelitz BI. Clinical trials in ulcerative colitis: II. Historical review. Am J Gastroenterol 1988;83:227–43.PubMedGoogle Scholar
  20. 20.
    Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;(2):CD000543.PubMedGoogle Scholar
  21. 21.
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005;100:2478–85.PubMedCrossRefGoogle Scholar
  23. 23.
    Azad-Khan AK, Howes DT, Piris J, Truelove SC. Optimum dose of sulphasalazine for maintenance treatment of ulcerative colitis. Gut 1980;21:232–40.PubMedCrossRefGoogle Scholar
  24. 24.
    Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cocahrane Database Syst Rec 2006;(2):CD000544.Google Scholar
  25. 25.
    Green JR, Lobo AJ, Holdsworth CD, et al. Balsalazide is more effective and better tolerated than mesalamine in treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology 1998;114:15–22.PubMedCrossRefGoogle Scholar
  26. 26.
    Safdi M. DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in treatment of distal ulcerative colitis. Am J Gastroenterol 1997;92: 1867–71.Google Scholar
  27. 27.
    Ferry GD, Kirschner BS, Grand RJ, et al. Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. J Pediatr Gastroenterol Nutr 1993;17:32–8.PubMedCrossRefGoogle Scholar
  28. 28.
    D’Agata ID, Vanounou T, Seidman E. Mesalamine in pediatric inflammatory bowel disease: a 10-year experience. Inflamm Bowel Dis 1996;2:229–35.CrossRefGoogle Scholar
  29. 29.
    Summers RW, Switz DM, Sessions JT Jr, et al. National cooperative crohn disease study: results of drug treatment. Gastroenterology 1979;77:847–69.PubMedGoogle Scholar
  30. 30.
    Hanauer SB, Sandborn W. Management of Crohn disease in adults. Am J Gastroenterol 2001;96:635–43.PubMedCrossRefGoogle Scholar
  31. 31.
    Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004;2:379–88.PubMedCrossRefGoogle Scholar
  32. 32.
    Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997;113:1465–73.PubMedCrossRefGoogle Scholar
  33. 33.
    Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn disease. Cochrane Database Syst Rev 2005;(1):CD003715.PubMedGoogle Scholar
  34. 34.
    Travis SPL, Stange EF, Lémann M, et al. European evidence based consensus on the diagnosis and management of Crohn disease: current management. Gut 2006;55:16–35.CrossRefGoogle Scholar
  35. 35.
    Griffiths A, Koletzko S, Sylvester F, et al.. Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn disease. J Pediatr Gastroenterol Nutr 1993;17:186–92.PubMedGoogle Scholar
  36. 36.
    Achkar JP, Hanauer SB. Medical therapy to reduce postoperative Crohn disease recurrence. Am J Gastroenterol 2000;95:1139–46.PubMedCrossRefGoogle Scholar
  37. 37.
    Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of postoperative relapse in Crohn disease with mesalamine: European Cooperative Crohn Disease Study VI. Gastroenterology 2000;118:264–73.PubMedCrossRefGoogle Scholar
  38. 38.
    Caprilli R, Cottone M, Tonelli F, et al. Two mesalazine regimens in the prevention of post-operative recurrence of Crohn disease: a pragmatic, double-blind, randomized controlled trial. Aliment Pharmacol Ther 2003;17:517–23.PubMedCrossRefGoogle Scholar
  39. 39.
    Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postooperative maintenance of Crohn disease remission with 6-mercaptopurine, mesalamine or placebo: a 2-year trial. Gastroenterology 2004;127:723–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn disease. Gastroenterology 2004;127:730–40.PubMedCrossRefGoogle Scholar
  41. 41.
    Eaden JA, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000;14:145–53.PubMedCrossRefGoogle Scholar
  42. 42.
    Rubin DT, LoSavio A, Yadron N, et al. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol 2006;4:1346–50.PubMedCrossRefGoogle Scholar
  43. 43.
    Van Staa TP, Card T, Logan RF, Leufkens HGM. 5-aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiologic study. Gut 2005;54:1573–78.PubMedCrossRefGoogle Scholar
  44. 44.
    Bernstein CN, Blanchard JF, Metge C, Yogendran M. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 2003;98:2784–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2005;100:1345–53.PubMedCrossRefGoogle Scholar
  46. 46.
    Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451–9.Google Scholar
  47. 47.
    Huls G, Koornstra JJ, Kleibeuker JH. Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinoma. Lancet 2003;362:230–2.PubMedCrossRefGoogle Scholar
  48. 48.
    Bernstein CN, Eaden J, Steinhart AH, et al. Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. Inflamm Bowel Dis 2002;8:356–61.PubMedCrossRefGoogle Scholar
  49. 49.
    Baker DE, Kane S. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis. Rev Gastroenterol Disord 2004;4:86–91.PubMedGoogle Scholar
  50. 50.
    Ransford RA, Langman MJS. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002;51:536–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Loftus EV, Kane SV, Bjorkman D. Systematic review: Short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004;19:179–89.PubMedCrossRefGoogle Scholar
  52. 52.
    Tolia V. Sulfasalazine desensitization in children and adolescents with chronic inflammatory bowel disease. Am J Gastroenterol 1992;87:1029–32.PubMedGoogle Scholar
  53. 53.
    Giaffer MH, O’Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant to or allergic to sulphasalazine. Aliment Pharmacol Ther 1992;6:51–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Barden L, Lipson A, Pert P, et al. Mesalazine in childhood inflammatory bowel disease. Aliment Pharmacol Ther 1989;3:597–603.PubMedCrossRefGoogle Scholar
  55. 55.
    Norgard B, Fomager K, Pedersen L. Birth outcome in women exposed to 5-ASA during pregnancy: a Danish cohort study. Gut 2003;52:243–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Norgard B, Puho E, Pedersen L, et al. Risk of congenital anomalies in children born to women with ulcerative colitis: a population-based, case-control study. Am J Gastroenterol 2003;98:2006–10.PubMedGoogle Scholar
  57. 57.
    Diav-Citrin O, Park YH, Veerasuntharam G, et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998;114:23–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Connell W, Miller A. Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy. Drug Saf 1999;21:311–23.PubMedCrossRefGoogle Scholar
  59. 59.
    Klotz U, Harings-Kaim A. Negligible excretion of 5-aminosalicylic acid in breast milk. Lancet 1993;342:618–9.PubMedCrossRefGoogle Scholar
  60. 60.
    American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776–89.Google Scholar
  61. 61.
    Levy RL, Feld AD. Increasing patient adherence to gastrointestinal treatment and prevention regimens. Am J Gastroenterol 1999;94:1733–42.PubMedCrossRefGoogle Scholar
  62. 62.
    Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006;23:577–85.PubMedCrossRefGoogle Scholar
  63. 63.
    Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003;1:170–3.PubMedCrossRefGoogle Scholar
  64. 64.
    Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005;11:421–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Baker D. MMX.™ mesalamine. Rev Gastroenterol Disord 2006;6:146–52.PubMedGoogle Scholar
  66. 66.
    Marakhouski U, Fixa B, Holoman J, et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Aliment Pharmacol Ther 2005;21:133–40.PubMedCrossRefGoogle Scholar
  67. 67.
    Forbes A, Al-Damluji A, Ashworth S, et al. Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2005;21:1099–1104.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • M. Susan Moyer
    • 1
  1. 1.Division of GI, Hepatology & NutritionCincinnati Children’s Hospital Medical CenterCincinnatiUSA

Personalised recommendations